China Shineway Pharmaceutical Group Limited Defensive Interval Ratio
China Shineway Pharmaceutical Group Limited defensive interval ratio. China Shineway Pharmaceutical Group Limited (C1S) has a Defensive Interval Ratio of 172 days as of December 2025. Defensive assets of €1.18 Billion (cash €-, short-term investments €376.64 Million, receivables €805.93 Million) cover 172 days of daily cash needs of €6.88 Million/day. See China Shineway Pharmaceutical Group Limi short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Defensive Interval Ratio
Defensive Assets
Daily Cash Need
Current Liabilities
Defensive Interval Ratio of China Shineway Pharmaceutical Group Limited (2013–2025)
Defensive interval ratio of China Shineway Pharmaceutical Group Limited from 2013 to 2025. This chart shows how China Shineway Pharmaceutical Group Limited's Defensive Interval Ratio has evolved across 13 annual periods from 2013 to 2025. As of December 2025, the ratio stands at 172 days, meaning defensive assets of €1.18 Billion can fund 172 days of operations without new revenue. Check how resilient are China Shineway Pharmaceutical Group Limi's assets to evaluate the company's liquid asset resilience ratio.
China Shineway Pharmaceutical Group Limited Defensive Interval Ratio by Year (2013–2025)
China Shineway Pharmaceutical Group Limited defensive interval ratio by year from 2013 to 2025. The table below presents the year-by-year Defensive Interval Ratio for China Shineway Pharmaceutical Group Limited from 2013 to 2025, covering 13 annual filings. Each row shows defensive assets, daily cash need, the DIR in days, and the change in days compared to the prior year. For the complete balance sheet picture, see China Shineway Pharmaceutical Group Limi asset portfolio.
| Year | DIR (days) | Defensive Assets (EUR) | Daily Cash Need | Cash | ST Investments | Change (days) |
|---|---|---|---|---|---|---|
| 2025 | 172 days | €1.18 Billion | €6.88 Million/day | €- | €376.64 Million | ▼ -15 days |
| 2024 | 187 days | €1.26 Billion | €6.71 Million/day | €- | €350.02 Million | ▲ +71 days |
| 2023 | 117 days | €778.21 Million | €6.67 Million/day | €- | €20.00 Million | ▼ -35 days |
| 2022 | 152 days | €693.61 Million | €4.56 Million/day | €- | €20.23 Million | ▲ +11 days |
| 2021 | 141 days | €424.46 Million | €3.01 Million/day | €- | €- | ▲ +46 days |
| 2020 | 95 days | €311.79 Million | €3.27 Million/day | €- | €- | ▼ -121 days |
| 2019 | 216 days | €697.05 Million | €3.23 Million/day | €- | €- | ▼ -44 days |
| 2018 | 260 days | €556.65 Million | €2.14 Million/day | €- | €7.19 Million | ▼ -35 days |
| 2017 | 295 days | €573.07 Million | €1.94 Million/day | €- | €16.91 Million | ▼ -7 days |
| 2016 | 302 days | €556.06 Million | €1.84 Million/day | €- | €- | ▲ +35 days |
| 2015 | 266 days | €511.86 Million | €1.92 Million/day | €- | €- | ▲ +22 days |
| 2014 | 245 days | €593.82 Million | €2.43 Million/day | €- | €- | ▲ +34 days |
| 2013 | 210 days | €680.05 Million | €3.23 Million/day | €- | €- | — |